Owing to osimertinib efficacy on brain metastases demonstrated in large Phase 3 trials in patients with or without T790M mutation [20, 21], osimertinib should also be considered the first-line treatment of choice in EGFR-mutant lung cancer patients with choroidal metastases. Here, EGFR is linked to lung carcinoma.